Insights into the antimicrobial properties of hepcidins: Advantages and drawbacks as potential therapeutic agents

Molecules

Volumn 20, Issue 4, 2015, Pages 6319-6341

  Lombardi, Lisa ^a   Maisetta, Giuseppantonio ^a   Batoni, Giovanna ^a   Tavanti, Arianna ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Antibacterial activity; Antifungal activity; Antimicrobial peptides; Hepcidins

Indexed keywords

ANTIFUNGAL AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; HEPCIDIN; PEPTIDE HYDROLASE;

ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIUM; CHEMISTRY; DRUG EFFECTS; HUMAN; LIVER; PH;

ANIMALS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; DRUG RESISTANCE, BACTERIAL; HEPCIDINS; HUMANS; HYDROGEN-ION CONCENTRATION; LIVER; PEPTIDE HYDROLASES;

EID: 84928709947     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20046319     Document Type: Review

References (126)

1. Alanis, A.J. Resistance to antibiotics: Are we in the post-antibiotic era? Arch. Med. Res. 2005, 36, 697-705.
2. Fair, R.J.; Tor, Y. Antibiotics and bacterial resistance in the 21st century. Perspect. Med. Chem. 2014, 28, 25-64.
3. Schäberle, T.F.; Hack, I.M. Overcoming the current deadlock in antibiotic research. Trends Microbiol. 2014, 22, 165-167.
4. Stanton, T.B. A call for antibiotic alternatives research. Trends Microbiol. 2013, 21, 111-113.
5. Aoki, W.; Ueda, M. Characterization of antimicrobial peptides toward the development of novel antibiotics. Pharmaceuticals 2013, 6, 1055-1081.
6. Roscia, G.; Falciani, C.; Bracci, L.; Pini, A. The development of antimicrobial peptides as new antibacterial drugs. Curr. Protein Pept. Sci. 2013, 14, 641-649.
7. Yeung, A.T.; Gellatly, S.L.; Hancock, R.E. Multifunctional cationic host defense peptides and their clinical applications. Cell. Mol. Life Sci. 2011, 68, 2161-2176.
8. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389-395.
9. Jenssen, H.; Hamill, P.; Hancock, R.E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 2006, 19, 491-511.
10. Brown, K.L.; Hancock, R.E.W. Cationic host defense (anti-microbial) peptides. Curr. Opin. Immunol. 2006, 18, 24-30.
11. Hancock, R.E.W.; Brown, K.L. Mookherjee, N. Host defence peptides from invertebrates - Emerging antimicrobial strategies. Immunobiology 2006, 211, 315-322.
12. Mookherjee, N.; Hancock, R.E.W. Cationic host defence peptides: Innate immune regulatory peptides as a novel approach for treating infections. Cell. Mol. Life Sci. 2007, 64, 922-933.
13. Hancock, R.E.W. Peptide antibiotics. Lancet 1997, 349, 418-422.
14. Hancock, R.E.W. Cationic peptides: Effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 2004, 1, 156-164.
15. Marr, A.K.; Gooderham W.J.; Hancock, R.E.W. Antibacterial peptides for therapeutic use: Obstacles and realistic outlook. Curr. Opin. Pharmacol. 2006, 6, 468-472.
16. Seo, M.D.; Won, H.S.; Kim, J.H.; Mishig-Ochir, T.; Lee, B.J. Antimicrobial Peptides for Therapeutic Applications: A Review. Molecules 2012, 17, 12276-12286.
17. Yount, N.Y.; Yeaman, M.R. Mechanisms of Antimicrobial Peptide Action and Resistance. Pharmacol. Rev. 2003, 55, 27-55.
18. Nguyen, L.T.; Haney, E.F.; Vogel, H.J. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011, 29, 464-472.
19. Teixeira, V.; Feio, M.J.; Bastos, M. Role of lipids in the interaction of antimicrobial peptides with membranes. Prog. Lipid Res. 2012, 51, 149-177.
20. Huang, Y.; Huang, J.; Chen, Y. Alpha-helical cationic antimicrobial peptides: Relationships of structure and function. Protein Cell 2010, 1, 143-152.
21. Yount, N.Y.; Yeaman, M.R. Peptide antimicrobials: Cell wall as a bacterial target. Ann. N. Y. Acad. Sci. 2013, 1277, 127-138.
22. Brogden, K.A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 2005, 3, 238-250.
23. Maisetta, G.; Petruzzelli, R.; Brancatisano, F.L.; Esin, S.; Vitali, A.; Campa, M.; Batoni, G. Antimicrobial activity of human hepcidin 20 and 25 against clinically relevant bacterial strains: Effect of copper and acidic pH. Peptides 2010, 31, 1995-2002.
24. Maisetta, G.; Vitali, A.; Scorciapino, M.A.; Rinaldi, A.C.; Petruzzelli, R.; Brancatisano, F.L.; Esin, S.; Stringaro, A.; Colone, M.; Luzi, C.; et al . pH-dependent disruption of Escherichia coli ATCC 25922 and model membranes by the human antimicrobial peptides hepcidin 20 and 25. FEBS J. 2013, 280, 2842-2854.
25. Oberparleiter, C.; Kaiserer, L.; Haas, H.; Ladurner, P.; Andratsch, M.; Marx, F. Active internalization of the Penicillium chrysogenum antifungal protein PAF in sensitive aspergilli. Antimicrob. Agents Chemother.2003, 47, 3598-3601.
26. De Coninck, B.; Cammue, B.P.A.; Thevissen, K. Modes of antifungal action and in planta functions of plant defensins and defensin-like peptides. Fungal Biol. Rev. 2013, 26, 109-120.
27. Kragol, G.; Lovas, S.; Varadi, G.; Condie, B.A.; Hoffmann, R.; Otvos, L., Jr. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 2001, 40, 3016-3026.
28. Brotz, H.; Bierbaum, G.; Reynolds, P.E.; Sahl, H.G. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur. J. Biochem. 1997, 246, 193-199.
29. Guanì-Guerra, E.; Santos-Mendoza, T.; Lugo-Reyes, S.O.; Teran, L.M. Antimicrobial peptides: General overview and clinical implications in human health and disease. Clin. Immunol. 2010, 135, 1-11.
30. Cunliffe, R.N.; Mahida, Y.R. Expression and regulation of antimicrobial peptides in the gastrointestinal tract. J. Leukoc. Biol. 2004, 75, 49-58.
31. Zasloff, M. Inducing endogenous antimicrobial peptides to battle infections. Proc. Natl. Acad. Sci. USA 2006, 103, 8913-8914.
32. Steinstraesser, L.; Koehler, T.; Jacobsen, F.; Daigeler, A.; Goertz, O.; Langer, S.; Kesting, M.; Steinau, H.; Eriksson, E.; Hirsch, T. Host defense peptides in wound healing. Mol. Med. 2008, 14, 528-537.
33. Jenssen, H.; Hancock, R.E.W. Therapeutic potential of HDPs as immunomodulatory agents. Methods Mol. Biol. 2010, 618, 329-347.
34. Mookherjee, N.; Brown, K.L.; Bowdish, D.M.; Doria, S.; Falsafi, R.; Hokamp, K.; Roche, F.M.; Mu, R.; Doho, G.H.; Pistolic, J.; et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. 2006, 176, 2455-2464.
35. Krause, A.; Neitz, S.; Mägert, H.J.; Schulz, A.; Forssmann, W.G.; Schulz-Knappe, P.; Adermann, K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000, 480, 147-150.
36. Park, C.H.; Valore, E.V.; Waring, A.J.; Ganz, T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 2001, 276, 7806-7810.
37. Hunter, H.N.; Fulton, D.B.; Ganz, T.; Vogel, H.J. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J. Biol. Chem. 2002, 277, 37597-37603.
38. Barthe, C.; Hocquellet, A.; Garbay, B. Bacteriostatic activity of the proregion of human hepcidin. Protein Pept. Lett. 2011, 18, 36-40.
39. Melino, S.; Gallo, M.; Trotta, E.; Mondello, F.; Paci, M.; Petruzzelli, R. Metal-binding and nuclease activity of an antimicrobial peptide analogue of the salivary histatin 5. Biochemistry 2006, 45, 15373-15383.
40. Nemeth, E.; Tuttle, M.S.; Powelson, J.; Vaughn, M.B.; Donovan, A.; Ward, D.M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306, 2090-2093.
41. Oliveira Filho, J.P.; Badial, P.R.; Cunha, P.H.J.; Cruz, T.F.; Araujo, J.P., Jr.; Divers, T.J.; Winand, N.J.; Borges, A.S. Cloning, sequencing and expression analysis of the equine hepcidin gene by realtime PCR. Vet. Immunol. Immunopathol. 2010, 135, 34-42.
42. Khangembam, V.C.; Kumar, A. Buffalo hepcidin: Characterization of cDNA and study of antimicrobial property. Vet. Res. Commun. 2011, 35, 79-87.
43. Boumaiza, M.; Ezzine, A.; Jaouen, M.; Sari, M.-A.; Marzouki, N. Molecular characterization of a novel hepcidin (HepD) from Camelus dromedaries. Synthetic peptide forms exhibit antibacterial activity. J. Pept. Sci. 2014, 20, 680-688.
44. Badial, P.R.; Oliveira Filho, J.P.; Cunha, P.H.J.; Cagnini, D.Q.; Araújo, J.P., Jr.; Winand, N.J.; Borges, A.S. Identification, characterization and expression analysis of hepcidin gene in sheep. Res. Vet. Sci. 2011, 90, 443-450.
45. Díaz, V.; Gammella, E.; Recalcati, S.; Santambrogio, P.; MongeNaldi, A.; Vogel, J.; Gassmann, M.; Cairo, G. Liver iron modulates hepcidin expression during chronically elevated erythropoiesis in mice. Hepatology 2013, 58, 2122-2132.
46. Hilton, K.B.; Lambert, L.A. Molecular evolution and characterization of hepcidin gene products in vertebrates. Gene 2008, 415, 40-48.
47. Roetto, A.; Papanikolaou, G.; Politou, M.; Alberti, F.; Girelli, D.; Christakis, J.; Loukopoulos, D.; Camaschella, C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat. Genet. 2003, 33, 21-22.
48. Martens, R.J.; Mealey, K.; Cohen, N.D.; Harrington, J.R.; Chaffin, M.K.; Taylor, R.J.; Bernstein, L.R. Pharmacokinetics of gallium maltolate after intragastric administration in neonatal foals. Am. J. Vet. Res. 2007, 68, 1041-1044.
49. Jacobsen, S.; Jensen, J.C.; Frei, S.; Jensen, A.L.; Thoefner, M.B. Use of serum amyloid A and other acute phase reactans to monitor the inflammatory response after castration in horses: A field study. Equine Vet. J. 2005, 37, 552-556.
50. Cuesta, A.; Meseguer, J.; Esteban, M.A. The antimicrobial peptide hepcidin exerts an important role in the innate immunity against bacteria in the bony fish gilthead seabream. Mol. Immunol. 2008, 45, 2333-2342.
51. Shike, H.; Lauth, X.; Westerman, M.E.; Ostland, V.E.; Carlberg, J.M.; van Olst, J.C.; Shimizu, C.; Bulet, P.; Burns, J.C. Bass hepcidin is a novel antimicrobial peptide induced by bacterial challenge. Eur. J. Biochem. 2002, 269, 2232-2237.
52. Hocquellet, A.; le Senechal, C.; Garbay, B. Importance of the disulfide bridges in the antibacterial activity of human hepcidin. Peptides 2012, 36, 303-307.
53. Kearse, M.; Moir, R.; Wilson, A.; Stones-Havas, S.; Cheung, M.; Sturrock, S.; Buxton, S.; Cooper, A.; Markowitz, S.; Duran, C.; et al. Geneious Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 2012, 28, 1647-1649.
54. Nemth, E.; Preza, G.C.; Jung, C.L.; Kablan, J.; Waring, A.J.; Ganz, T. The N-terminus of Hepcidin is essential for its interaction with ferropoitin: Structure-function study. Blood 2006, 107, 328-333.
55. De Domenico, I.; Nemeth, E.; Nelson, J.M.; Phillips, J.D.; Ajioka, R.S.; Kay, M.S.; Kushner, J.P.; Ganz, T.; Ward, D.M.; Kaplan, J. The hepcidin-binding site on ferroportinis evolutionarily conserved. Cell Metab. 2008, 8, 146-156.
56. Rydengård, V.; Andersson, E.N.; Schmidtchen, A. Zinc potentiates the antibacterial effects of histidine-rich peptides against Enterococcus faecalis. FEBS J. 2006, 273, 2399-2406.
57. Wang, M.; Liu, L.H.; Wang, S.; Li, X.; Lu, X.; Gupta, D.; Dziarski, R. Human peptidoglycan recognition proteins requires zinc to kill both Gram-positive and Gram negative bacteria and are synergistic with antibacterial peptides. J. Immunol. 2007, 178, 3116-3125.
58. Cabras, T.; Patamia, M.; Melino, S.; Inzitari, R.; Messana, I.; Castagnola, M.; Petruzzelli, R. Pro-oxidant activity of histatin 5 related Cu(II)-model peptide probed by mass spectrometry. Biochem. Biophys. Res. Commun. 2007, 358, 277-284.
59. Houghton, E.A.; Nicholas, K.M. In vitro reactive oxygen species production by histatins and copper(I,II). J. Biol. Inorg. Chem. 2009, 14, 243-251.
60. Aschi, M.; Bozzi, A.; Di Bartolomeo, R.; Petruzzelli, R. The role of disulfide bonds and N-terminus in the structural properties of hepcidins: Insights from molecular dynamics simulations. Biopolymers 2010, 93, 917-926.
61. Klüver, E.; Schulz-Maronde, S.; Scheid, S.; Meyer, B.; Forssmann, W.G.; Adermann, K. Structure-activity relation of human beta-defensin 3: Influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry 2005, 44, 9804-9816.
62. Schroeder, B.O.; Wu, Z.; Nuding, S.; Groscurth, S.; Marcinowski, M.; Beisner, J.; Buchner, J.; Schaller, M.; Stange, E.F.; Wehkamp, J. Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature 2011, 7, 419-423.
63. Altamura, S.; Kiss, J.; Blattmann, C.; Gilles, W.; Muckenthaler, M.U. SELDI-TOF MS detection of urinary hepcidin. Biochimie 2009, 91, 1335-1338.
64. Ganz, T.; Olbina, G.; Girelli, D.; Nemeth, E.; Westerman, M. Immunoassay for human serum hepcidin. Blood 2008, 12, 4292-4297.
65. Mason, A.J.; Gasnier, C.; Kichler, A.; Prévost, G.; Aunis, D.; Metz-Boutigue, M.H.; Bechinger, B. Enhanced membrane disruption and antibiotic action against pathogenic bacteria by designed histidine-rich peptides at acidic pH. Antimicrob. Agents Chemother. 2006, 50, 3305-3311.
66. Van Kan, E.J.; Demel, R.A.; van der Bent, A.; de Kruijff, B. The role of the abundant phenylalanines in the mode of action of the antimicrobial peptide clavanin. Biochim. Biophys. Acta 2003, 1, 84-92.
67. Li, L.; He, J.; Eckert, R.; Yarbrough, D.; Lux, R.; Anderson, M.; Shi, W. Design and characterization of an acid-activated antimicrobial peptide. Chem. Biol. Drug Des. 2010, 75, 127-132.
68. Yoo, S.; Kim, J.Y.; Park, S.C.; Choi, Y.; Seo, C.H.; Hahm, K.S.; Park, Y. Effect of acidic pH on antibacterial action of peptide isolated from Korean pen shell (Atrinapectinata). J. Pept. Sci. 2011, 17, 353-357.
69. Skerlavaj, B.; Benincasa, M.; Risso, A.; Zanetti, M.; Gennaro, R. SMAP-29: A potent antibacterial and antifungal peptide from sheep leukocytes. FEBS Lett. 1999, 463, 58-62.
70. Matsuzaki, K.; Sugishita, K.; Harada, M.; Fujii, N.; Miyajima, K. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Biochim. Biophys. Acta 1997, 1327, 119-130.
71. Mangoni, M.L.; Papo, N.; Barra, D.; Simmaco, M.; Bozzi, A.; Di Giulio, A.; Rinaldi, A.C. Effects of the antimicrobial peptide temporin L on cell morphology, membrane permeability and viability of Escherichia coli . Biochem. J. 2004, 380, 859-865.
72. Hartmann, M.; Berditsch, M.; Hawecker, J.; Ardakani, M.F.; Gerthsen, D.; Ulrich, A.S. Damage of the bacterial cell envelope by antimicrobial peptides gramicidin S and PGLa as revealed by transmission and scanning electron microscopy. Antimicrob. Agents Chemother. 2010, 54, 3132-3142.
73. Pfaller, M.A.; David, R.A.; Diekema, D.J.; Horn, D.L.; Reboli, A.C.; Franks, B.; Azie, N.E. Epidemiology and outcomes of invasive Candidiasis due to non-albicans species of Candida in 2,496 patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004-2008. PLoS ONE 2014, 9, e101510.
74. Tumbarello, M.; Sanguinetti, M.; Trecarichi, E.M.; la Sorda, M.; Rossi, M.; de Carolis, E.; de Gaetano Donati, K.; Fadda, G.; Cauda, R.; Posteraro, B. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: Risk factors, antifungal treatment and outcome. J. Antimicrob. Chemother. 2008, 62, 1379-1385.
75. Kennedy, M.A.; Sobel, J.D. Vulvovaginal candidiasis caused by non-albicans Candida species: New insights. Curr. Infect. Dis. Rep. 2010, 12, 465-470.
76. Miceli, M.H.; Díaz, J.A.; Lee, S.A. Emerging opportunistic yeast infection. Lancet Infect. Dis. 2011, 11, 142-151.
77. Benincasa, M.; Scocchi, M.; Pacor, S.; Tossi, A.; Nobili, D.; Basaglia, G.; Busetti, M.; Gennaro, R. Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts. J. Antimicrob. Chemother. 2006, 58, 950-959.
78. Helmerhorst, E.J.; Reijnders, I.M.; van't Hof, W.; Simoons-Smit, I.; Veerman, E.C.; Amerongen, A.V. Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob. Agents Chemother. 1999, 43, 702-704.
79. Joly, S.; Maze, C.; McCray, P.B., Jr.; Guthmiller, J.M. Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J. Clin. Microbiol. 2004, 42, 1024-1029.
80. Lee, J.; Hwang, J.S.; Hwang, I.S.; Cho, J.; Lee, E.; Kim, Y.; Lee, D.G. Coprisin-induced antifungal effects in Candida albicans correlate with apoptotic mechanisms. Free Radic. Biol. Med. 2012, 52, 2302-2311.
81. Helmerhorst, E.J.; Venuleo, C.; Beri, A.; Oppenheim, F.G. Candida glabrata is unusual with respect to its resistance to cationic antifungal proteins. Yeast 2005, 22, 705-14.
82. Tavanti, A.; Maisetta, G.; Del Gaudio, G.; Petruzzelli, R.; Sanguinetti, M.; Batoni, G.; Senesi, S. Fungicidal activity of the human peptide hepcidin 20 alone or in combination with other antifungals against Candida glabrata isolates. Peptides 2011, 32, 2484-2487.
83. Kondori, N.; Baltzer, L.; Dolphin, G.T.; Mattsby-Balzer, I. Fungicidal activity of human lactoferrin-derived peptides based on the antimicrobial αβ region. Int. J. Antimicrob. Agents 2011, 37, 51-57.
84. Richter, S.S.; Galask, R.P.; Messer, S.A.; Hollis, R.J.; Diekema, D.J.; Pfaller, M.A. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J. Clin. Microbiol. 2005, 43, 2155-2162.
85. Pfaller, M.A. Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 2012, 125 (Suppl. 1), S3-S13.
86. Ostrosky-Zeichner, L. Candida glabrata and FKS mutations: Witnessing the emergence of the true Multidrug-Resistant Candida. Clin. Infect. Dis. 2013, 56, 1733-1734.
87. Wei, G.X.; Bobek, L.A. Human salivary mucin MUC7 12-mer-L and 12-mer-D peptides: Antifungal activity in saliva, enhancement of activity with protease inhibitor cocktail or EDTA, and cytotoxicity to human cells. Antimicrob. Agents Chemother. 2005, 49, 2336-2342.
88. Batoni, G.; Maisetta, G.; Esin, S.; Campa, M. Human beta-defensin-3: A promising antimicrobial peptide. Mini Rev. Med. Chem. 2006, 6, 1063-1073.
89. Wei, G.X.; Campagna, A.N.; Bobek, L.A. Factors affecting antimicrobial activity of MUC7 12-mer, a human salivary mucin-derived peptide. Ann. Clin. Microbiol. Antimicrob. 2007, 6, 14-17.
90. Maisetta, G.; Di Luca, M.; Esin, S.; Florio, W.; Brancatisano, F.L.; Bottai, D.; Campa, M.; Batoni, G. Evaluation of the inhibitory effects of human serum components on bactericidal activity of human beta defensin 3. Peptides 2008, 29, 1-6.
91. Del Gaudio, G.; Lombardi, L.; Maisetta, G.; Esin, S.; Batoni, G.; Sanguinetti, M.; Senesi, S.; Tavanti, A. Antifungal activity of the non cytotoxic human peptide hepcidin 20 against fluconazole resistant Candida glabrata in human vaginal fluid. Antimicrob. Agents Chemother. 2013, 57, 4314-4321.
92. Valore, E.V.; Park, C.H.; Igreti, S.L.; Ganz, T. Antimicrobial components of vaginal fluid. Am. J. Obstet. Gynecol. 2002, 187, 561-568.
93. Shaw, J.L.; Smith, C.R.; Diamandis, E.P. Proteomic analysis of human cervico-vaginal fluid. J. Proteome Res. 2007, 6, 2859-2865.
94. Singh, P.K.; Tack, B.F.; McCray, P.B., Jr.; Welsh, M.J. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am. J. Physiol. Lung Cell Mol. Physiol. 2000, 279, L799-L805.
95. Zaritsky, J.; Young, B.; Gales, B.; Wang, H.; Rastogi, A.; Westerman, M.; Nemeth, E.; Ganz, T.; Salusky, I.B. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin. J. Am. Soc. Nephrol. 2010, 5, 1010-1014.
96. Høiby, N.; Bjarnsholt, T.; Givskov, M.; Molin, S.; Ciofu, O. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 2010, 35, 322-332.
97. Høiby, N.; Bjarnsholt, T.; Moser, C.; Bassi, G.L.; Coenye, T.; Donelli, G.; Hall-Stoodley, L.; Holá, V.; Imbert, C.; Kirketerp-Møller, K.; et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin. Microbiol. Infect. 2015, doi:10.1016/j.cmi.2014.10.024.
98. Hall-Stoodley, L.; Stoodley, P. Evolving concepts in biofilm infections. Cell Microbiol. 2009, 11, 1034-1043.
99. Batoni, G.; Maisetta, G.; Brancatisano, F.L.; Esin, S.; Campa, M. Use of antimicrobial peptides against microbial biofilms: Advantages and limits. Curr. Med. Chem. 2011, 18, 256-279.
100. Di Luca, M., Maccari, G.; Nifosì, R. Treatment of microbial biofilms in the post-antibiotic era: Prophylactic and therapeutic use of antimicrobial peptides and their design by bioinformatics tools. Pathog. Dis. 2014, 70, 257-270.
101. Anunthawan, T.; de la Fuente-Núñez, C.; Hancock, R.E.; Klaynongsruang, S. Cationic amphipathic peptides KT2 and RT2 are taken up into bacterial cells and kill planktonic and biofilm bacteria. Biochim. Biophys. Acta 2015, 1848, 1352-1358.
102. Zhao, G.; Zhong, H.; Zhang, M.; Hong, Y. Effects of antimicrobial peptides on Staphylococcus aureus growth and biofilm formation in vitro following isolation from implant-associated infections. Int. J. Clin. Exp. Med. 2015, 8, 1546-1551.
103. Dosler, S.; Karaaslan, E. Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides. Peptides 2014, 62, 32-37.
104. Mansour, S.C.; de la Fuente-Núñez, C.; Hancock, R.E. Peptide IDR-1018: Modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections. J. Pept. Sci. 2014, doi:10.1002/psc.2708.
105. Di Luca, M.; Maccari, G.; Maisetta, G.; Batoni, G. BaAMPs: The database of biofilm-active antimicrobial peptides. Biofouling 2015, 31, 193-199.
106. Fey, P.D.; Olson, M.E. Current concepts in biofilm formation of Staphylococcus epidermidis. Future Microbiol. 2010, 5, 917-933.
107. Kogan, G.; Sadovskaya, I.; Chaignon, P.; Chokr, A.; Jabbouri, S. Biofilms of clinical strains of Staphylococcus that do not contain polysaccharide intercellular adhesin. FEMS Microbiol. Lett. 2006, 255, 11-16.
108. Brancatisano, F.L.; Maisetta, G.; Di Luca, M.; Esin, S.; Bottai, D.; Bizzarri, R.; Campa, M.; Batoni, G. Inhibitory effect of the human liver-derived antimicrobial peptide hepcidin 20 on biofilms of polysaccharide intercellular adhesin (PIA)-positive and PIA-negative strains of Staphylococcus epidermidis. Biofouling 2014, 30, 435-446.
109. Segev-Zarko, L.A.; Saar-Dover, R.; Brumfeld, V.; Mangoni, M.L.; Shai, Y. Mechanisms of biofilm inhibition and degradation by antimicrobial peptides. Biochem. J. 2015, doi:10.1042/BJ20141251.
110. Brouwera, C.P.J.M.; Rahmanb, M.; Welling, M.M. Discovery and development of a synthetic peptide derived from lactoferrin for clinical use. Peptides 2011, 32, 1953-1963.
111. Patch, J.A.; Barron, A.E. Mimicry of bioactive peptides via non-natural, sequence-specific peptidomimetic oligomers. Curr. Opin. Chem. Biol. 2002, 6, 872-877.
112. Ryan, L.K.; Freeman, K.B.; Masso-Silva, J.A.; Falkovsky, K.; Aloyouny, A.; Markowitz, K.; Hise, A.G.; Fatahzadeh, M.; Scott, R.W.; Diamond, G. Activity of potent and selective host defense peptide mimetics in mouse models of oral Candidiasis. Antimicrob. Agents Chemother. 2014, 58, 3820-3827.
113. Fjell, C.D.; Hiss, J.A.; Hancock, R.E.W.; Schneider, G. Designing antimicrobial peptides: Form follows function. Nat. Rev. Drug Discov. 2012, 11, 37-51.
114. Liu, Z.; Young, A.W.; Hu, P.; Rice, A.J.; Zhou, C.; Zhang, Y.; Kallenbach, N.R. Tuning the membrane selectivity of antimicrobial peptides by using multivalent design. ChemBioChem 2007, 8, 2063-2065.
115. Arnusch, C.J.; Albada, H.B.; van Vaardegem, M.; Liskamp, R.M.; Sahl, H.G.; Shadkchan, Y.; Osherov, N.; Shai, Y. Trivalent ultrashort lipopeptides are potent pH dependent antifungal agents. J. Med. Chem. 2012, 55, 1296-1302.
116. Lakshminarayanan, R.; Liu, S.; Li, J.; Nandhakumar, M.; Aung, T.T.; Goh, E.; Chang, J.Y.; Saraswathi, P.; Tang, C.; Safie, S.R.; et al. Synthetic multivalent antifungal peptides effective against fungi. PLoS ONE 2014, 9, e87730.
117. Urbán, P.; Valle-Delgado, J.J.; Moles, E.; Marques, J.; Díez, C.; Fernàndez-Busquets, X. Nanotools for the delivery of antimicrobial peptides. Curr. Drug Targets 2012, 13, 1158-1172.
118. Li, X., Li, P.; Saravanan, R.; Basu, A.; Mishra, B.; Lim, S.H.; Su, X.; Tambyah, P.A.; Leong, S.S. Antimicrobial functionalization of silicone surfaces with engineered short peptides having broad spectrum antimicrobial and salt-resistant properties. Acta Biomat. 2014, 10, 258-266.
119. Piras, A.M.; Maisetta, G., Sandreschi, S.; Esin, S.; Gazzarri, M.; Batoni, G.; Chiellini, F. Preparation, physical-chemical and biological characterization of chitosan nanoparticles loaded with lysozyme. Int. J. Biol. Macromol. 2014, 67, 124-131.
120. Piras, A.M.; Sandreschi, S.; Maisetta, G.; Esin, S.; Batoni, G.; Chiellini, F. Chitosan Nanoparticles for the Linear Release of Model Cationic Peptide. Pharm. Res. 2015, doi:10.1007/s11095-014-1615-9.
121. Chikakane, K.; Takahashi, H. Measurement of skin pH and its significance in cutaneous diseases. Clin. Dermatol. 1995, 13, 299-306.
122. Hickey, R.J.; Zhou, X.; Pierson, J.D.; Ravel, J.; Forney, L.J. Understanding vaginal microbiome complexity from an ecological perspective. Transl. Res. 2012, 160, 267-282.
123. Liu, Y.L.; Nascimento, M.; Burne, R.A. Progress toward understanding the contribution of alkali generation in dental biofilms to inhibition of dental caries. Int. J. Oral Sci. 2012, 4, 135-140.
124. Schwarz, P.; Kübler, J.A.; Strnad, P.; Müller, K.; Barth, T.F.; Gerloff, A.; Feick, P.; Peyssonnaux, C.; Vaulont, S.; Adler, G.; et al . Hepcidin is localised in gastric parietal cells, regulates acid secretion and is induced by Helicobacter pylori infection. Gut 2012, 61, 193-201.
125. Sow, F.B.; Florence, W.C.; Satoskar, A.R.; Schlesinger, L.S.; Zwilling, B.S.; Lafuse, W.P. Expression and localization of hepcidin in macrophages: A role in host defence against tuberculosis. J. Leukoc. Biol. 2007, 82, 934-945.
126. Heitz, F.; Morris, M.C.; Divita, G. Twenty years of cell-penetrating peptides: From molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009, 157, 195-206.